DNJ-20

Overview

DNJ-20 is an α-glucosidase inhibitor ( IC 50 : 55.3 μg/mL). DNJ-20 has broad-spectrum anti- SARS-CoV-2 activity. DNJ-20 inhibits the correct processing of viral glycoproteins by interfering with the endoplasmic reticulum-associated glycoprotein folding process (ERQC), thereby blocking the formation and infection of viral particles. DNJ-20 has IC 50 values up to 1.49 uM against several SARS-CoV-2 variants, as well as HCoV-229E and HCoV-0C43。DNJ-20 can be used for pan-coronavirus research.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Signaling Pathways > Glycosidase | Products > Signaling Pathways > SARS-CoV

Product Information

• Catalog No.: HY-173411
• CAS No.: 3081926-49-7
• Molecular Formula: C31H41NO10
• Molecular Weight: 587.66
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source